Top Markets
#1 Trillions Trillions +4,372.65%
#2 Ozapay Ozapay +38.33%
#3 Aria.AI Aria.AI +21.33%
#4 TRIA TRIA +14.00%
#5 Zano Zano +12.45%
#6 Osaka Protocol Osaka Protocol +12.26%
#7 DeXe DeXe +11.85%
#8 River Pts River Pts +11.61%
#9 pippin pippin +9.94%
#10 Janction Janction +9.42%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Share Price
$0.28545656
Market Cap
$4.50M
Change (1 day)
5.97%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
Earnings for Acticor Biotech SAS (ALACT)
Earnings in Jun 2024 TTM: $-12.93M
According to Acticor Biotech SAS latest financial reports the company's current earnings are $-12.93M. In 2022 the company made an earning of $-19.33M, a decrease compared to its 2021 earnings that were of $-16.54M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Acticor Biotech SAS from 2010 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -158,354.90%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -36,019.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -40,564.29%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -16,637.04%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -12,587.97%
AU